Sahajanand Medical Technologies Limited IPO
15 Oct 2026 – 19 Oct 2026
Issue Details
- Price Band
- ₹327 – ₹344
- Lot Size
- 43 shares
- Min Investment
- ₹14,792 (1 lot · 43 shares)
- Face Value
- ₹1
- Offer for Sale
- 1,38,22,116 shares (to selling holders)
- Issue Size
- Initial Public Offer comprising of Offer for sale upto 13,822,116 Equity Shares (Including Eligible Employees Reservation Portion of up to 2,50,000 Equity Shares)
- Registrar
- MUFG Intime India Pvt.Ltd. ↗
Timetable
GMP History
Latest GMP ₹41 · Last updated 13 Oct 2026, 9:49 pm IST
The graph appears from the second day of GMP data.
| Date | GMP | GMP % | Change | Est. Listing | Updated (IST) |
|---|---|---|---|---|---|
| 13 Oct | ₹41 | +11.9% | — | ₹385 |
Subscription
Subscription figures appear once bidding opens.
Financials
All values in ₹ crore
About Sahajanand Medical Technologies
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium. The product portfolio spans three key categories: Vascular Intervention (VI): Includes coronary stents and balloons for minimally invasive blood vessel treatments. Structural Heart (SH): Covers advanced technologies such as Transcatheter Aortic Valve Implantation (TAVI) and Occluders. Other Products: Includes renal stents, peripheral Drug-Coated Balloons (DCBs), and selected trading products. Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists. The company has built a robust intellectual property base, with 102 patents granted globally and 71 pending patent applications, along with five design registrations in India. Key products such as Supraflex Cruz (DES) , Hydra (TAVI) , and Cocoon (Occluders) are backed by 72 clinical studies, and are widely accepted in over 76 countries across Europe, Asia, and other regions. The global distribution strategy includes direct operations in key European markets (Germany, Spain, France, UK), hybrid models in India (serving hospitals like Narayana Hrudayalaya Limited), and distributor-led entry in markets such as Italy. International market adoption is reinforced by endorsements from key opinion leaders (KOLs), successful government tenders, and partnerships with major Group Purchasing Organizations (GPOs) in Europe. The company follows a “House of Brand” strategy, developing and commercializing clinically differentiated products under recognized brand names like Supraflex Cruz, Hydra, and Cocoon.
As published in the company's own offer documents.
Strengths
- Extensive global sales and marketing network.
- Strong research and development capabilities.
- Diversified and integrated manufacturing facilities.
- Leadership in India and key international markets.
- Proven M&A and strategic collaboration capabilities.
- Technologically advanced medical devices in high-barrier segments.
- Experienced leadership team backed by reputed institutional investors.
As stated by the company in its prospectus — not our assessment.
The company's own risk factors are not shown here. They run to dozens of pages in the Red Herring Prospectus, under “Risk Factors”, and are worth the read before applying.
Lead Managers
- Motilal Oswal Investment Advisors Limited
- Avendus Capital Private Limited
- HSBC Securities
- Capital Markets (India) Private Limited
- Nuvama Wealth Management Limited
Offer details
Application sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min)one lot, the smallest bid allowed | 1 | 43 | ₹14,792 |
| Retail (max)most that stays under ₹2L | 13 | 559 | ₹1,92,296 |
| S-HNI (min)first bid over ₹2L | 14 | 602 | ₹2,07,088 |
| S-HNI (max)most that stays under ₹10L | 67 | 2,881 | ₹9,91,064 |
| B-HNI (min)first bid over ₹10L | 68 | 2,924 | ₹10,05,856 |
Priced at the top of the band, which is what a cut-off bid pays. Retail ends at ₹2,00,000 and S-HNI at ₹10,00,000; these are SEBI's limits, not the issuer's.
Issue mechanics
- Issue Type
- Book Building
- Minimum Order
- 43 Equity Shares
- Categories
- FI, IC, MF, FII, OTH, CO, IND, NOH and EMP
- UPI Eligible
- IND and EMP (upto 5 Lakhs)
- Max Bid (Retail)
- Rs. 2,00,000
- Max Bid (Employee)
- Rs. 5,00,000
- Tick Size
- Re. 1
- Bidding Hours
- 10.00 a.m. to 5.00 p.m.
- UPI Mandate Cut-off
- 19-Oct-2026 (upto 5:00 PM) The new cut-off time for UPI mandate acceptance is 05:00 PM on last day of IPO bidding. Further bids with confirmed status of mandate amount blocked (RC100) shall be considered as valid applications and hence, investors are advised to submit their UPI applications in IPO well in advance to avoid any last minute technical/systemic constraints that may hamper their ability
- Sponsor Bank
- Axis Bank Limited and Kotak Mahindra Bank Limited
Registrar
- Name
- MUFG Intime India Pvt.Ltd.
- Address
- C-101, Embassy 247, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
- Contact
- Shanti Gopalkrishnan, +91 810 811 4949 , Tel: +91 810 811 4949, sahajanandmedical.ipo@in.mpms.mufg.com
Documents
- Red Herring ProspectusThe full offer documentPDF
- Basis of Issue PriceHow the band was arrived atPDF
- Application FormThe blank ASBA form, as filedPDF
- Bidding CentresWhere a physical form can be handed inPDF
- Security ParametersTick size, lot and limits as filed with the exchangePDF
Published by NSE as ZIP archives; opened here as the PDF inside.
Collected from NSE and public sources. Always confirm against the prospectus before applying.
In the news
- The Economic Times
Sahajanand Medical Technologies sets IPO price band at Rs 327-344 per share; issue opens on Oct 15
Sahajanand Medical Technologies has set a price band of Rs 327-344 per share for its Rs 475.48 crore IPO, which opens on October 15 and closes on October 19. The issue is entirely…
- The Economic Times
IPO calendar: After a week of lull, 5 companies to raise nearly Rs 1,600 crore this week
Five IPOs are scheduled to open for subscription next week, including mainboard issues from HD Fire Protect, Fusion CX and Sahajanand Medical Technologies. The three mainboard…
Headlines from The Economic Times, matched to this company by name. Reproduced as published — not our reporting, and not investment advice. More IPO news
Frequently Asked Questions
What is the GMP of Sahajanand Medical Technologies Limited IPO today?
The latest grey market premium for Sahajanand Medical Technologies Limited IPO is ₹41. GMP is unofficial and indicative only — it is not a guarantee of listing price.
What is the price band of Sahajanand Medical Technologies Limited IPO?
The price band is ₹327 – ₹344, with a lot size of 43 shares. The minimum investment is ₹14,792.
When does Sahajanand Medical Technologies Limited IPO open and close?
The issue opens on 15 Oct 2026 and closes on 19 Oct 2026. Listing is expected on 23 Oct 2026.
Who is the registrar for Sahajanand Medical Technologies Limited IPO?
MUFG Intime India Pvt.Ltd. is the registrar. Allotment status can be checked on the registrar's website once allotment is finalised.